CN102118969B - 组胺h4受体的二氨基吡啶、二氨基嘧啶和二氨基哒嗪调节剂 - Google Patents
组胺h4受体的二氨基吡啶、二氨基嘧啶和二氨基哒嗪调节剂 Download PDFInfo
- Publication number
- CN102118969B CN102118969B CN200980131846.6A CN200980131846A CN102118969B CN 102118969 B CN102118969 B CN 102118969B CN 200980131846 A CN200980131846 A CN 200980131846A CN 102118969 B CN102118969 B CN 102118969B
- Authority
- CN
- China
- Prior art keywords
- amine
- methylamino
- pyrrolidin
- pyrimidin
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CN(C1)CC1N(*)* Chemical compound CN(C1)CC1N(*)* 0.000 description 9
- QVFGNOOULWCILC-KOLCDFICSA-N C(C1)C1Nc1nccc(N2C[C@@H]3NCC[C@@H]3C2)n1 Chemical compound C(C1)C1Nc1nccc(N2C[C@@H]3NCC[C@@H]3C2)n1 QVFGNOOULWCILC-KOLCDFICSA-N 0.000 description 1
- LMGMAZHTWLCFFM-UHFFFAOYSA-N C(CC1C2)C2CC1Nc1nccc(N2CCNCC2)n1 Chemical compound C(CC1C2)C2CC1Nc1nccc(N2CCNCC2)n1 LMGMAZHTWLCFFM-UHFFFAOYSA-N 0.000 description 1
- ODDFZMBCXMJJQX-UHFFFAOYSA-N C(CC1C2)C2CC1Nc1nncc(N2CCNCCC2)c1 Chemical compound C(CC1C2)C2CC1Nc1nncc(N2CCNCCC2)c1 ODDFZMBCXMJJQX-UHFFFAOYSA-N 0.000 description 1
- FFHYOTOGQOXQPD-UHFFFAOYSA-N C(CNc1nccc(N2CCCC2)c1)c1ccccc1 Chemical compound C(CNc1nccc(N2CCCC2)c1)c1ccccc1 FFHYOTOGQOXQPD-UHFFFAOYSA-N 0.000 description 1
- NJQDSPOBYQQRKX-MIDVRCEHSA-N C/C=N\C(\CNc1nccc(N(CC2)C[C@H]2N)n1)=C/C#C Chemical compound C/C=N\C(\CNc1nccc(N(CC2)C[C@H]2N)n1)=C/C#C NJQDSPOBYQQRKX-MIDVRCEHSA-N 0.000 description 1
- BFOHFKMAUOEGIM-SAPNQHFASA-N C/N=C(\CC1)/CN1c1nc(NCC2CCCCC2)ncc1 Chemical compound C/N=C(\CC1)/CN1c1nc(NCC2CCCCC2)ncc1 BFOHFKMAUOEGIM-SAPNQHFASA-N 0.000 description 1
- ZZPQCQWVWDUPSI-LLVKDONJSA-N CC(C)(C)CNc1nccc(N(CC2)C[C@@H]2NC)n1 Chemical compound CC(C)(C)CNc1nccc(N(CC2)C[C@@H]2NC)n1 ZZPQCQWVWDUPSI-LLVKDONJSA-N 0.000 description 1
- MRVWJRIQMZIMNY-UHFFFAOYSA-N CC(C)(C)CNc1nccc(N2CCNCC2)n1 Chemical compound CC(C)(C)CNc1nccc(N2CCNCC2)n1 MRVWJRIQMZIMNY-UHFFFAOYSA-N 0.000 description 1
- QLMBEWNADHIWHO-UHFFFAOYSA-N CC(C)(C)CNc1nncc(N(C)CCN)c1 Chemical compound CC(C)(C)CNc1nncc(N(C)CCN)c1 QLMBEWNADHIWHO-UHFFFAOYSA-N 0.000 description 1
- QBBFMKPAYRCLPC-UHFFFAOYSA-N CC(C)(C)CNc1nncc(N2CCN(C)CC2)c1 Chemical compound CC(C)(C)CNc1nncc(N2CCN(C)CC2)c1 QBBFMKPAYRCLPC-UHFFFAOYSA-N 0.000 description 1
- HPRVXQDCTCTNJI-UHFFFAOYSA-N CC(C)(C)Nc1nccc(N(C2)CC2NC)c1 Chemical compound CC(C)(C)Nc1nccc(N(C2)CC2NC)c1 HPRVXQDCTCTNJI-UHFFFAOYSA-N 0.000 description 1
- AKTIOUSKFDNOMX-VIFPVBQESA-N CC(C)(CNc1nccc(N(CC2)C[C@H]2N)n1)O Chemical compound CC(C)(CNc1nccc(N(CC2)C[C@H]2N)n1)O AKTIOUSKFDNOMX-VIFPVBQESA-N 0.000 description 1
- DFOBBMBDIYGENA-QYUUFKNNSA-N CC(C)([C@H]1C2)[C@H]2[C@@](C)(C2)[C@@H]1[C@H]2Nc1nccc(N2CCNCC2)n1 Chemical compound CC(C)([C@H]1C2)[C@H]2[C@@](C)(C2)[C@@H]1[C@H]2Nc1nccc(N2CCNCC2)n1 DFOBBMBDIYGENA-QYUUFKNNSA-N 0.000 description 1
- TXNYEDFVFQUNGH-SNVBAGLBSA-N CC(C)CNc1cc(N(CC2)C[C@@H]2N)cnn1 Chemical compound CC(C)CNc1cc(N(CC2)C[C@@H]2N)cnn1 TXNYEDFVFQUNGH-SNVBAGLBSA-N 0.000 description 1
- YDCMGULTZPJOLX-PAYTZWKFSA-N CC([C@H](C1)C(C)(C)[C@H]1C1)C1Nc1nccc(N2C[C@@H]3NCC[C@@H]3C2)c1 Chemical compound CC([C@H](C1)C(C)(C)[C@H]1C1)C1Nc1nccc(N2C[C@@H]3NCC[C@@H]3C2)c1 YDCMGULTZPJOLX-PAYTZWKFSA-N 0.000 description 1
- DWFOGLWBKKDYQU-MJVOBMLWSA-N CC([C@H](C1)C(C)(C)[C@H]1C1)C1Nc1nncc(N(C2)CC2NC)c1 Chemical compound CC([C@H](C1)C(C)(C)[C@H]1C1)C1Nc1nncc(N(C2)CC2NC)c1 DWFOGLWBKKDYQU-MJVOBMLWSA-N 0.000 description 1
- BROFGQDXVACYPP-MIGSVPMKSA-N CC1(C)C2C(CNc3nccc(N(CC4)C[C@@H]4N)n3)CCC1C2 Chemical compound CC1(C)C2C(CNc3nccc(N(CC4)C[C@@H]4N)n3)CCC1C2 BROFGQDXVACYPP-MIGSVPMKSA-N 0.000 description 1
- OKNUZJGCFLNZFG-UHFFFAOYSA-N CCCCNc1cc(N2CCNCC2)cnn1 Chemical compound CCCCNc1cc(N2CCNCC2)cnn1 OKNUZJGCFLNZFG-UHFFFAOYSA-N 0.000 description 1
- LMGIKPFGVTXTIL-UHFFFAOYSA-N CCCCNc1nccc(N2CCNCC2)n1 Chemical compound CCCCNc1nccc(N2CCNCC2)n1 LMGIKPFGVTXTIL-UHFFFAOYSA-N 0.000 description 1
- QAXRJLAQFRQDQS-UHFFFAOYSA-N CN(CC1)CCN1c1cc(NC2C(CC3)CC3C2)nnc1 Chemical compound CN(CC1)CCN1c1cc(NC2C(CC3)CC3C2)nnc1 QAXRJLAQFRQDQS-UHFFFAOYSA-N 0.000 description 1
- OBBDKTRQFPBRFX-UHFFFAOYSA-N CN(CC1)CCN1c1cc(NCC2CCCC2)ncc1 Chemical compound CN(CC1)CCN1c1cc(NCC2CCCC2)ncc1 OBBDKTRQFPBRFX-UHFFFAOYSA-N 0.000 description 1
- AZSGIHAKWXMCPI-UHFFFAOYSA-N CN(CC1)CCN1c1cc(NCCO)nnc1 Chemical compound CN(CC1)CCN1c1cc(NCCO)nnc1 AZSGIHAKWXMCPI-UHFFFAOYSA-N 0.000 description 1
- PLESHIVWLQHHAS-UHFFFAOYSA-N CNC(C1)CN1c1cc(NCC2CCCC2)ncc1 Chemical compound CNC(C1)CN1c1cc(NCC2CCCC2)ncc1 PLESHIVWLQHHAS-UHFFFAOYSA-N 0.000 description 1
- RBPJCXGCTIPLQQ-UHFFFAOYSA-N CNC(C1)CN1c1cc(NCc2ccccc2)ncc1 Chemical compound CNC(C1)CN1c1cc(NCc2ccccc2)ncc1 RBPJCXGCTIPLQQ-UHFFFAOYSA-N 0.000 description 1
- JBLQLUZSATWYRP-UHFFFAOYSA-N CNC(C1)CN1c1ccnc(NCc(cc2)ccc2F)n1 Chemical compound CNC(C1)CN1c1ccnc(NCc(cc2)ccc2F)n1 JBLQLUZSATWYRP-UHFFFAOYSA-N 0.000 description 1
- FYWWTWHYFTWIRD-ZDUSSCGKSA-N CN[C@@H](CC1)CN1c1cc(NC2CCCC2)ncc1 Chemical compound CN[C@@H](CC1)CN1c1cc(NC2CCCC2)ncc1 FYWWTWHYFTWIRD-ZDUSSCGKSA-N 0.000 description 1
- QLDXTDXXBCKZJH-LBPRGKRZSA-N CN[C@@H](CC1)CN1c1cc(NC2CCCC2)nnc1 Chemical compound CN[C@@H](CC1)CN1c1cc(NC2CCCC2)nnc1 QLDXTDXXBCKZJH-LBPRGKRZSA-N 0.000 description 1
- JUVKHEZWYMMAAF-ZDUSSCGKSA-N CN[C@@H](CC1)CN1c1cc(NCC2CCCC2)nnc1 Chemical compound CN[C@@H](CC1)CN1c1cc(NCC2CCCC2)nnc1 JUVKHEZWYMMAAF-ZDUSSCGKSA-N 0.000 description 1
- LZABSKVJZGMKQU-JTQLQIEISA-N CN[C@@H](CC1)CN1c1nc(NC2CC2)ncc1 Chemical compound CN[C@@H](CC1)CN1c1nc(NC2CC2)ncc1 LZABSKVJZGMKQU-JTQLQIEISA-N 0.000 description 1
- HFBXVWPBZRXZSP-SNVBAGLBSA-N CN[C@H](CC1)CN1c1cc(NCCCO)nnc1 Chemical compound CN[C@H](CC1)CN1c1cc(NCCCO)nnc1 HFBXVWPBZRXZSP-SNVBAGLBSA-N 0.000 description 1
- OLMDCLNAEFIAAG-SNVBAGLBSA-N CN[C@H](CC1)CN1c1cc(NCCOC)nnc1 Chemical compound CN[C@H](CC1)CN1c1cc(NCCOC)nnc1 OLMDCLNAEFIAAG-SNVBAGLBSA-N 0.000 description 1
- BRZAJFBRWPNASH-SECBINFHSA-N COCCNc1cc(N(CC2)C[C@@H]2N)cnn1 Chemical compound COCCNc1cc(N(CC2)C[C@@H]2N)cnn1 BRZAJFBRWPNASH-SECBINFHSA-N 0.000 description 1
- NDQFQCMPGLOPIQ-CYBMUJFWSA-N C[C@H](c1ccccc1)Nc1cc(N2CCNCC2)cnn1 Chemical compound C[C@H](c1ccccc1)Nc1cc(N2CCNCC2)cnn1 NDQFQCMPGLOPIQ-CYBMUJFWSA-N 0.000 description 1
- MNAQKNMQPXWADC-TZMCWYRMSA-N C[C@H](c1ccccc1)Nc1nccc(N(CC2)C[C@@H]2N)n1 Chemical compound C[C@H](c1ccccc1)Nc1nccc(N(CC2)C[C@@H]2N)n1 MNAQKNMQPXWADC-TZMCWYRMSA-N 0.000 description 1
- HRAVLWRABOTGHJ-BMFZPTHFSA-N C[C@H](c1ccccc1)Nc1nccc(N2C[C@@H]3NCC[C@@H]3C2)n1 Chemical compound C[C@H](c1ccccc1)Nc1nccc(N2C[C@@H]3NCC[C@@H]3C2)n1 HRAVLWRABOTGHJ-BMFZPTHFSA-N 0.000 description 1
- IZPDUYKVJZFDRR-UHFFFAOYSA-N Fc1ccc(CNc2nccc(N3CCNCC3)c2)cc1 Chemical compound Fc1ccc(CNc2nccc(N3CCNCC3)c2)cc1 IZPDUYKVJZFDRR-UHFFFAOYSA-N 0.000 description 1
- CAQPOUUEWMPIGV-UHFFFAOYSA-N Fc1ccc(CNc2nncc(N3CCNCC3)c2)cc1 Chemical compound Fc1ccc(CNc2nncc(N3CCNCC3)c2)cc1 CAQPOUUEWMPIGV-UHFFFAOYSA-N 0.000 description 1
- BQFYRGMWIRCYBO-SLDMJWGPSA-N N[C@H](CC1)CN1c1cc(NCC2C(CC3)CC3C2)nnc1 Chemical compound N[C@H](CC1)CN1c1cc(NCC2C(CC3)CC3C2)nnc1 BQFYRGMWIRCYBO-SLDMJWGPSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Otolaryngology (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6103908P | 2008-06-12 | 2008-06-12 | |
| US61/061039 | 2008-06-12 | ||
| US11442508P | 2008-11-13 | 2008-11-13 | |
| US11441608P | 2008-11-13 | 2008-11-13 | |
| US61/114425 | 2008-11-13 | ||
| US61/114416 | 2008-11-13 | ||
| PCT/US2009/047033 WO2009152325A1 (en) | 2008-06-12 | 2009-06-11 | Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h4 receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102118969A CN102118969A (zh) | 2011-07-06 |
| CN102118969B true CN102118969B (zh) | 2017-03-08 |
Family
ID=41417123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200980131846.6A Expired - Fee Related CN102118969B (zh) | 2008-06-12 | 2009-06-11 | 组胺h4受体的二氨基吡啶、二氨基嘧啶和二氨基哒嗪调节剂 |
Country Status (20)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE478067T1 (de) | 2006-03-31 | 2010-09-15 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyridine und pyrazine als modulatoren des histamin-h4-rezeptors |
| UA100567C2 (ru) * | 2008-06-12 | 2013-01-10 | Янссен Фармацевтика Нв | Использование антагонистов н4-гистаминовых рецепторов для лечения послеоперационных спаек |
| KR101600278B1 (ko) | 2008-06-12 | 2016-03-08 | 얀센 파마슈티카 엔.브이. | 히스타민 h4 수용체의 다이아미노-피리딘, 피리미딘, 및 피리다진 조절제 |
| US9371311B2 (en) | 2008-06-30 | 2016-06-21 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine derivatives |
| PE20120325A1 (es) * | 2009-05-19 | 2012-04-12 | Dow Agrosciences Llc | Aminopirimidinas sustituidas con arilo como agentes fungicidas |
| WO2011078143A1 (ja) * | 2009-12-22 | 2011-06-30 | 塩野義製薬株式会社 | ピリミジン誘導体およびそれらを含有する医薬組成物 |
| CN104363908B (zh) * | 2012-05-30 | 2017-12-22 | 霍夫曼-拉罗奇有限公司 | 吡咯烷基杂环类 |
| JO3516B1 (ar) | 2013-03-06 | 2020-07-05 | Janssen Pharmaceutica Nv | مُعدِّلات بنزإيميدازول-2-يل بيريميدين لمستقبل الهستامين h4 |
| WO2014147586A1 (en) * | 2013-03-22 | 2014-09-25 | Novartis Ag | 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh |
| CN104903312B (zh) * | 2013-10-07 | 2019-01-29 | 卡德门企业有限公司 | Rho激酶抑制剂 |
| JP6625610B2 (ja) | 2014-07-31 | 2019-12-25 | ビーエーエスエフ ソシエタス・ヨーロピアBasf Se | ピラゾールの調製方法 |
| CN107592859A (zh) | 2015-05-11 | 2018-01-16 | 巴斯夫欧洲公司 | 制备4‑氨基哒嗪类的方法 |
| US20190216790A1 (en) * | 2016-10-13 | 2019-07-18 | The Regents Of The University Of California | Methods for Treating Pruritis |
| WO2018082964A1 (en) | 2016-11-04 | 2018-05-11 | Basf Se | Process for the production of pyridazinyl-amides in a one-pot synthesis |
| JP2022165429A (ja) * | 2019-10-02 | 2022-11-01 | Meiji Seikaファルマ株式会社 | ヒスタミンh4受容体調節作用を有する新規トリアジン誘導体 |
| KR20240031347A (ko) * | 2021-07-01 | 2024-03-07 | 에어리 파마슈티컬즈, 인코포레이티드 | 아제티디닐 피리미딘 및 그의 용도 |
| CN116354937B (zh) * | 2021-12-27 | 2025-07-11 | 江苏恩华药业股份有限公司 | 吡啶(嘧啶)胺类衍生物及其应用 |
| EP4547660A1 (en) * | 2022-06-29 | 2025-05-07 | Alcon Inc. | Azetidinyl pyrimidines and uses thereof as jak inhibitors |
| JP2025530372A (ja) * | 2022-09-15 | 2025-09-11 | クルゲン(シャンハイ),インク. | 修飾タンパク質ならびにタンパク質結合剤および分解剤 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005054239A1 (en) * | 2003-12-05 | 2005-06-16 | Bayer Healthcare Ag | 2-aminopyrimidine derivatives |
| WO2007072163A2 (en) * | 2005-12-20 | 2007-06-28 | Pfizer Limited | Pyrimidine derivatives |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE759371A (fr) | 1969-11-24 | 1971-05-24 | Bristol Myers Co | Azaspirodecanediones heterocycliques et procedes pour leur preparation |
| GB8609630D0 (en) | 1986-04-19 | 1986-05-21 | Pfizer Ltd | Anti-arrhythmia agents |
| HU206337B (en) | 1988-12-29 | 1992-10-28 | Mitsui Petrochemical Ind | Process for producing pyrimidine derivatives and pharmaceutical compositions |
| MX9203454A (es) | 1989-12-28 | 1992-08-01 | Upjohn Co | Compuestos anti sida diaromaticos substituidos. |
| US5449676A (en) * | 1991-04-26 | 1995-09-12 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Pyridazines |
| AU6003099A (en) * | 1998-10-06 | 2000-04-26 | Takeda Chemical Industries Ltd. | Fused pyridazine compounds, process for the preparation of the same and uses thereof |
| CA2396693A1 (en) | 1999-12-28 | 2001-07-05 | Stephen T. Wrobleski | Cytokine, especially tnf-alpha, inhibitors |
| AU2001290912A1 (en) | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| SE0004245D0 (sv) | 2000-11-20 | 2000-11-20 | Pharmacia Ab | Novel compounds and their use |
| WO2002072548A2 (en) | 2001-03-09 | 2002-09-19 | Ortho-Mcneil Pharmaceutical, Inc. | Heterocyclic compounds and their use as histamine h4 ligands. |
| US6825198B2 (en) | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
| IL161662A0 (en) * | 2001-11-01 | 2004-09-27 | Janssen Pharmaceutica Nv | Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors (gsk3 inhibitors) |
| EP1485378B1 (en) | 2002-03-13 | 2008-06-18 | Janssen Pharmaceutica N.V. | Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase |
| CA2476583C (en) | 2002-03-13 | 2011-07-05 | Kristof Van Emelen | Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
| CN100396679C (zh) * | 2002-03-13 | 2008-06-25 | 詹森药业有限公司 | 用作组蛋白脱乙酰化酶抑制剂的哌嗪基、哌啶基和吗啉基衍生物 |
| EP1571146A4 (en) | 2002-12-10 | 2010-09-01 | Ono Pharmaceutical Co | NITROGENIC HETEROCYCLIC COMPOUNDS AND THEIR MEDICAL USE |
| EP1437348A1 (fr) | 2003-01-13 | 2004-07-14 | L'oreal | Dérivés de de la 6-méthyl-pyrimidine-2,4-diamine, procédé de synthèse, compositions les comprenant et utilisations comme agents neutralisants basiques |
| EP1505064A1 (en) | 2003-08-05 | 2005-02-09 | Bayer HealthCare AG | 2-Aminopyrimidine derivatives |
| JP2007522233A (ja) * | 2004-02-11 | 2007-08-09 | アムジエン・インコーポレーテツド | バニロイド受容体リガンド及び治療におけるそれらの使用 |
| EP1812113A1 (en) | 2004-11-11 | 2007-08-01 | Argenta Discovery Limited | Pyrimidine compounds as histamine modulators |
| ATE412636T1 (de) | 2004-12-16 | 2008-11-15 | Hoffmann La Roche | Piperazinylpyridinderivate als mittel gegen adipositas |
| US20090306038A1 (en) * | 2005-09-13 | 2009-12-10 | Carceller Gonzalez Elena | 2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity |
| EP1767537A1 (en) | 2005-09-21 | 2007-03-28 | Cellzome (UK) Ltd. | Pyrimidine compounds for the treatment of inflammatory disorders |
| ES2327972T3 (es) * | 2006-01-19 | 2009-11-05 | Janssen Pharmaceutica, N.V. | Derivados de aminofenil como nuevos inhibidores de histona deacetilasa. |
| WO2007090853A1 (en) | 2006-02-10 | 2007-08-16 | Cellzome (Uk) Ltd. | Enantiomers of amino pyrimidine compounds for the treatment of inflammatory disorders |
| WO2007090854A1 (en) | 2006-02-10 | 2007-08-16 | Cellzome (Uk) Ltd. | Azetidine amino pyrimidine compounds for the treatment of inflammatory disorders |
| EP1829879A1 (en) | 2006-02-10 | 2007-09-05 | Cellzome (UK) Ltd. | Amino pyrimidine compounds for the treatment of inflammatory disorders |
| ATE478067T1 (de) | 2006-03-31 | 2010-09-15 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyridine und pyrazine als modulatoren des histamin-h4-rezeptors |
| GB0610909D0 (en) | 2006-06-05 | 2006-07-12 | Merck Sharp & Dohme | Therapeutic treatment |
| EP2066645A2 (en) * | 2006-09-12 | 2009-06-10 | UCB Pharma S.A. | 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions |
| EP1920654A1 (en) | 2006-09-13 | 2008-05-14 | Syngeta Participations AG | Novel pyridopyrazine N-oxides |
| US7985745B2 (en) | 2006-10-02 | 2011-07-26 | Abbott Laboratories | Method for pain treatment |
| WO2008074445A1 (en) | 2006-12-18 | 2008-06-26 | Ucb Pharma, S.A. | Novel tricyclic and heterotricyclic derivatives, processes for preparing them, pharmaceutical compositions thereof |
| CL2008000467A1 (es) | 2007-02-14 | 2008-08-22 | Janssen Pharmaceutica Nv | Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma |
| WO2008122378A1 (en) | 2007-04-04 | 2008-10-16 | Ucb Pharma, S.A. | Novel pyridine derivatives, processes for preparing them, pharmaceutical compositions thereof |
| WO2009068512A1 (en) | 2007-11-30 | 2009-06-04 | Palau Pharma, S. A. | 2 -amino-pyrimidine derivatives as histamine h4 antagonists |
| AR072084A1 (es) | 2008-06-12 | 2010-08-04 | Sanofi Aventis | Derivados de azacarbolinas, su preparacion y su utilizacion terapeutica como inhibidores de las quinasas pim |
| KR101600278B1 (ko) | 2008-06-12 | 2016-03-08 | 얀센 파마슈티카 엔.브이. | 히스타민 h4 수용체의 다이아미노-피리딘, 피리미딘, 및 피리다진 조절제 |
| JO2870B1 (en) | 2008-11-13 | 2015-03-15 | ميرك شارب اند دوهم كورب | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes |
| AU2009315754B2 (en) | 2008-11-13 | 2013-08-15 | F. Hoffmann-La Roche Ag | Spiro-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes |
-
2009
- 2009-06-11 KR KR1020117000733A patent/KR101600278B1/ko not_active Expired - Fee Related
- 2009-06-11 CA CA2727684A patent/CA2727684C/en not_active Expired - Fee Related
- 2009-06-11 EP EP09763614.6A patent/EP2315521B1/en active Active
- 2009-06-11 EA EA201170005A patent/EA018198B1/ru not_active IP Right Cessation
- 2009-06-11 MX MX2010013726A patent/MX2010013726A/es active IP Right Grant
- 2009-06-11 MY MYPI2010005857A patent/MY158927A/en unknown
- 2009-06-11 PE PE2010001130A patent/PE20110061A1/es active IP Right Grant
- 2009-06-11 NZ NZ589532A patent/NZ589532A/en not_active IP Right Cessation
- 2009-06-11 CN CN200980131846.6A patent/CN102118969B/zh not_active Expired - Fee Related
- 2009-06-11 US US12/997,567 patent/US8841287B2/en not_active Expired - Fee Related
- 2009-06-11 WO PCT/US2009/047033 patent/WO2009152325A1/en not_active Ceased
- 2009-06-11 JP JP2011513686A patent/JP5658662B2/ja not_active Expired - Fee Related
- 2009-06-11 AU AU2009257434A patent/AU2009257434B2/en not_active Ceased
- 2009-06-11 BR BRPI0915720-4A patent/BRPI0915720A2/pt not_active Application Discontinuation
-
2010
- 2010-11-25 IL IL209593A patent/IL209593A/en active IP Right Grant
- 2010-12-10 NI NI201000214A patent/NI201000214A/es unknown
- 2010-12-10 EC EC2010010675A patent/ECSP10010675A/es unknown
- 2010-12-13 CO CO10156304A patent/CO6321192A2/es not_active Application Discontinuation
-
2011
- 2011-01-11 ZA ZA2011/00298A patent/ZA201100298B/en unknown
- 2011-01-12 CR CR20110029A patent/CR20110029A/es not_active Application Discontinuation
-
2014
- 2014-08-14 US US14/460,217 patent/US9732087B2/en not_active Expired - Fee Related
-
2017
- 2017-06-28 US US15/636,325 patent/US20170298022A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005054239A1 (en) * | 2003-12-05 | 2005-06-16 | Bayer Healthcare Ag | 2-aminopyrimidine derivatives |
| WO2007072163A2 (en) * | 2005-12-20 | 2007-06-28 | Pfizer Limited | Pyrimidine derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2315521A1 (en) | 2011-05-04 |
| CA2727684C (en) | 2017-01-31 |
| AU2009257434A1 (en) | 2009-12-17 |
| CR20110029A (es) | 2011-07-06 |
| ZA201100298B (en) | 2012-06-27 |
| US20140357614A1 (en) | 2014-12-04 |
| JP2011524363A (ja) | 2011-09-01 |
| US20170298022A1 (en) | 2017-10-19 |
| EA018198B1 (ru) | 2013-06-28 |
| KR20110017441A (ko) | 2011-02-21 |
| AU2009257434B2 (en) | 2014-12-11 |
| CA2727684A1 (en) | 2009-12-17 |
| US9732087B2 (en) | 2017-08-15 |
| NI201000214A (es) | 2011-08-01 |
| CN102118969A (zh) | 2011-07-06 |
| US20110092474A1 (en) | 2011-04-21 |
| MX2010013726A (es) | 2011-01-14 |
| IL209593A (en) | 2015-02-26 |
| PE20110061A1 (es) | 2011-01-31 |
| BRPI0915720A2 (pt) | 2015-08-04 |
| KR101600278B1 (ko) | 2016-03-08 |
| JP5658662B2 (ja) | 2015-01-28 |
| HK1157569A1 (en) | 2012-07-06 |
| MY158927A (en) | 2016-11-30 |
| EA201170005A1 (ru) | 2011-08-30 |
| NZ589532A (en) | 2012-02-24 |
| EP2315521B1 (en) | 2014-05-21 |
| IL209593A0 (en) | 2011-01-31 |
| EP2315521A4 (en) | 2012-04-25 |
| US8841287B2 (en) | 2014-09-23 |
| ECSP10010675A (es) | 2011-01-31 |
| CO6321192A2 (es) | 2011-09-20 |
| WO2009152325A1 (en) | 2009-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2315521B1 (en) | Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h 4 receptor | |
| JP7514025B2 (ja) | Jak阻害剤化合物及びその使用 | |
| CN115192577B (zh) | Kras突变蛋白抑制剂 | |
| CN113286794B (zh) | Kras突变蛋白抑制剂 | |
| JP6609631B2 (ja) | 縮合環ヘテロアリール化合物及びtrk抑制剤としての用途 | |
| CA2767648C (en) | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors | |
| IL311187A (en) | Compressed ring compounds | |
| AU2014323777C1 (en) | Compound inhibiting activities of BTK and/or JAK3 kinases | |
| AU2022258377A1 (en) | Ring-modified proline short peptide compound and use thereof | |
| JP2023508772A (ja) | Jak阻害剤化合物及びその使用 | |
| CN102827170A (zh) | 治疗活性组合物和它们的使用方法 | |
| WO2005019218A1 (ja) | ピロロピリミジンチオン誘導体 | |
| TW201639827A (zh) | TGF-β抑制劑 | |
| CN113825755A (zh) | 作为irak4抑制剂的咪唑并吡啶类化合物 | |
| CN106660999A (zh) | 新化合物 | |
| WO2024149389A1 (zh) | 取代桥环类抑制剂及其制备方法和应用 | |
| CN113493453A (zh) | 稠合芳香环类衍生物、其制备方法及其在医药上的应用 | |
| CN114269736B (zh) | 一种酰胺化合物、药物组合物及其应用 | |
| US9371311B2 (en) | Benzoimidazol-2-yl pyrimidine derivatives | |
| HK1157569B (en) | Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h 4 receptor | |
| WO2026071137A1 (ja) | テトラヒドロピロロピリミジノン化合物及びその医薬用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170308 |